Bloomage Biotech(SH:688363) Xin Lang Cai Jing·2026-02-02 03:13Group 1 - The core viewpoint is that AI is accelerating the transformation of the healthcare industry, with significant growth potential in companies like Huaxi Biological, which expects a net profit increase of 54.93%-83.63% by 2025 [1] - Huaxi Biological's stock led the gains in the Sci-Tech Innovation Board, rising by 7.70%, indicating strong market interest and confidence in its future performance [1] - The Sci-Tech 100 ETF has shown significant liquidity and growth, with a recent trading volume of 1.74 billion yuan and a 1.32 billion yuan increase in scale over the past two weeks [1] Group 2 - According to Everbright Securities, AI has become a core productivity driver in the new infrastructure of healthcare, with AI drug development and AI medical imaging being the most mature sectors [2] - The future competition in the AI healthcare space will focus on exclusive high-quality private data and the ability to create closed-loop business scenarios [2] - The Sci-Tech 100 ETF closely tracks the Sci-Tech 100 Index, which focuses on high-growth sectors including semiconductors, pharmaceuticals, and new energy [2]